Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748241 | 0.73 | POLB (0.39) | POLBALDH1A1RAB9AATMOPRD1 | |
| SCHEMBL1748012 | 0.72 | HDAC6 (0.45) | ALDH1A1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL3318214 | 0.66 | SMN1; SMN2 (0.40) | POLBALDH1A1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL13417051 | 0.65 | LMNA (0.34) | POLBRAB9AATMOPRD1OPRM1 | |
| SCHEMBL27498299 | 0.64 | SLC1A2 (0.35) | POLBHSD11B1LMNA | |
| SCHEMBL3317022 | 0.64 | RAB9A (0.41) | POLBALDH1A1HSD11B1RAB9ALMNA | |
| SCHEMBL3317680 | 0.63 | NPC1 (0.46) | ALDH1A1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL3315274 | 0.62 | MAPK1 (0.45) | ALDH1A1RAB9AATMMAPTMAPK1 | |
| SCHEMBL475655 | 0.61 | GRM2 (0.34) | LMNA | |
| SCHEMBL5647514 | 0.61 | SLC1A2 (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | POLB 3459/4885ALDH1A1 199/4885HSD11B1 97/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | POLB 3459/4885ALDH1A1 199/4885HSD11B1 97/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | POLB 3459/4885ALDH1A1 199/4885HSD11B1 97/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | POLB 3459/4885ALDH1A1 199/4885HSD11B1 97/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | POLB 3459/4885ALDH1A1 199/4885HSD11B1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.